RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Clinical trials for RECURRENT GLIOBLASTOMA, IDH-WILDTYPE explained in plain language.
Never miss a new study
Get alerted when new RECURRENT GLIOBLASTOMA, IDH-WILDTYPE trials appear
Sign up with your email to follow new studies for RECURRENT GLIOBLASTOMA, IDH-WILDTYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug triapine paired with radiation targets recurrent brain cancers
Disease control Recruiting nowThis early-phase trial tests the safety and best dose of the drug triapine when given together with radiation therapy for people whose glioblastoma or astrocytoma has come back. Triapine works by blocking enzymes that cancer cells need to grow, while radiation kills cancer cells …
Matched conditions: RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Targeted radiation drug shows promise for tough brain tumors
Disease control Recruiting nowThis early-phase trial is testing a new radioactive drug, [177Lu]Lu-DOTA-EB-RGD2, in 24 patients with recurrent high-grade glioma, a fast-growing brain cancer. The drug is designed to seek out and deliver radiation directly to tumor blood vessels. It can be given through a vein o…
Matched conditions: RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Phase: EARLY_PHASE1 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Targeted radiation delivered directly to brain tumor cavity in new trial
Disease control Recruiting nowThis early-phase trial tests a single dose of a radioactive drug called [177Lu]Lu-XT771 in people with recurrent glioblastoma, an aggressive brain cancer. The drug is injected directly into the cavity left after tumor removal surgery, aiming to deliver radiation precisely to canc…
Matched conditions: RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Phase: EARLY_PHASE1 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells target deadly brain tumors in new trial
Disease control Recruiting nowThis early-phase trial tests the safety of a new treatment for people with recurrent or progressive high-grade glioma, a serious brain cancer. The therapy uses the patient's own immune cells, modified in a lab to recognize and attack tumor cells, and delivers them directly into t…
Matched conditions: RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug cocktail aims to outsmart recurrent glioblastoma
Disease control Recruiting nowThis study tests whether adding the drug selinexor to standard chemotherapy (temozolomide) can better control recurrent glioblastoma, an aggressive brain cancer. About 97 adults whose tumor has returned after initial treatment will receive either the combo or chemotherapy alone. …
Matched conditions: RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Experimental drug combo takes on recurrent glioblastoma
Disease control Recruiting nowThis early-stage trial tests two drugs—triapine and temozolomide—together in people whose glioblastoma has returned. The goal is to find the safest dose and see how well patients tolerate the combination. About 30 adults with recurrent grade 2-4 glioma will take part.
Matched conditions: RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE1 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental drug aims to boost immune attack on aggressive brain tumors
Disease control Recruiting nowThis phase 2 trial tests a new drug called GI-102, alone or with the immunotherapy pembrolizumab, given before surgery to people with recurrent or progressive glioblastoma (a fast-growing brain cancer). The goal is to see if these drugs can increase cancer-fighting immune cells i…
Matched conditions: RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Fat-Derived stem cells injected into brain during surgery to fight glioblastoma
Disease control Recruiting nowThis early-stage trial tests whether stem cells taken from fat tissue can be safely injected into the brain during surgery for recurrent glioblastoma. The stem cells are meant to attack remaining tumor cells and make them more sensitive to chemotherapy. About 20 adults whose brai…
Matched conditions: RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Experimental CAR-T therapy takes on deadly brain tumors
Disease control Recruiting nowThis early-phase trial tests a new treatment called P134 cells for people with recurrent glioblastoma, an aggressive brain cancer that has come back. P134 cells are immune cells engineered to target two proteins (CD44 and CD133) found on tumor cells. The study will enroll 26 adul…
Matched conditions: RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE1, PHASE2 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug combo aims to boost immune attack on returning brain tumors
Disease control Recruiting nowThis study tests two immunotherapy drugs, efineptakin alfa and pembrolizumab, in people whose glioblastoma (a type of brain cancer) has returned after standard treatment. The goal is to see if this combination can help the immune system fight the tumor and improve survival. About…
Matched conditions: RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Brain cancer breakthrough? new immunotherapy combo targets recurrent glioblastoma
Disease control Recruiting nowThis early-stage trial is testing a combination of two immunotherapy drugs, D2C7-IT and 2141-V11, for people with recurrent glioblastoma, a fast-growing brain cancer. The treatment is delivered directly into the brain after surgery, followed by injections near the neck to boost t…
Matched conditions: RECURRENT GLIOBLASTOMA, IDH-WILDTYPE
Phase: PHASE1 • Sponsor: Darell Bigner • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC